{"title":"Tuberculosis screening in hidradenitis suppurativa patients on tumor necrosis factor inhibitors: a retrospective chart review.","authors":"Katherine G Byrnes, Richard H Flowers","doi":"10.1093/ced/llaf014","DOIUrl":null,"url":null,"abstract":"<p><p>Hidradenitis suppurativa (HS) patients treated with tumor necrosis factor (TNF) inhibitors are at an increased risk for tuberculosis (TB) reactivation, necessitating baseline latent TB infection (LTBI) screening. However, evidence regarding the value of periodic LTBI screening in this population is limited. In this single-center retrospective chart review, we investigated the LTBI rate in HS patients treated with adalimumab or infliximab. The cohort included 92 patients with an average treatment duration of 37.4 months and a median Interferon-Gamma Release Assay (IGRA) number of 3. The cumulative observation time was 286 person-years. Our investigation found no positive LTBI results in HS patients on TNF inhibitors, challenging clinicians to reconsider the utility of serial screening for such patients who are otherwise at low risk for TB. Further research is essential for the development of evidence-based guidelines to optimize patient care and healthcare resource allocation.</p>","PeriodicalId":10324,"journal":{"name":"Clinical and Experimental Dermatology","volume":" ","pages":""},"PeriodicalIF":3.7000,"publicationDate":"2025-01-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical and Experimental Dermatology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1093/ced/llaf014","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"DERMATOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Hidradenitis suppurativa (HS) patients treated with tumor necrosis factor (TNF) inhibitors are at an increased risk for tuberculosis (TB) reactivation, necessitating baseline latent TB infection (LTBI) screening. However, evidence regarding the value of periodic LTBI screening in this population is limited. In this single-center retrospective chart review, we investigated the LTBI rate in HS patients treated with adalimumab or infliximab. The cohort included 92 patients with an average treatment duration of 37.4 months and a median Interferon-Gamma Release Assay (IGRA) number of 3. The cumulative observation time was 286 person-years. Our investigation found no positive LTBI results in HS patients on TNF inhibitors, challenging clinicians to reconsider the utility of serial screening for such patients who are otherwise at low risk for TB. Further research is essential for the development of evidence-based guidelines to optimize patient care and healthcare resource allocation.
期刊介绍：
Clinical and Experimental Dermatology (CED) is a unique provider of relevant and educational material for practising clinicians and dermatological researchers. We support continuing professional development (CPD) of dermatology specialists to advance the understanding, management and treatment of skin disease in order to improve patient outcomes.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
